GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » EBITDA per Share

CRNX (Crinetics Pharmaceuticals) EBITDA per Share : $-4.06 (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals EBITDA per Share?

Crinetics Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2024 was $-1.09. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.06.

During the past 3 years, the average EBITDA per Share Growth Rate was -16.20% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Crinetics Pharmaceuticals's EBITDA per Share or its related term are showing as below:

CRNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.6   Med: -16.2   Max: -6.1
Current: -16.2

During the past 8 years, the highest 3-Year average EBITDA per Share Growth Rate of Crinetics Pharmaceuticals was -6.10% per year. The lowest was -72.60% per year. And the median was -16.20% per year.

CRNX's 3-Year EBITDA Growth Rate is ranked worse than
72.56% of 1221 companies
in the Biotechnology industry
Industry Median: 5.1 vs CRNX: -16.20

Crinetics Pharmaceuticals's EBITDA for the three months ended in Sep. 2024 was $-87.03 Mil.

During the past 3 years, the average EBITDA Growth Rate was -44.10% per year. During the past 5 years, the average EBITDA Growth Rate was -49.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 8 years, the highest 3-Year average EBITDA Growth Rate of Crinetics Pharmaceuticals was -44.10% per year. The lowest was -107.60% per year. And the median was -55.80% per year.


Crinetics Pharmaceuticals EBITDA per Share Historical Data

The historical data trend for Crinetics Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crinetics Pharmaceuticals EBITDA per Share Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA per Share
Get a 7-Day Free Trial -2.19 -2.43 -2.78 -3.21 -3.81

Crinetics Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -0.93 -1.01 -1.04 -1.09

Crinetics Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Crinetics Pharmaceuticals's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-221.51/58.071
=-3.81

Crinetics Pharmaceuticals's EBITDA per Share for the quarter that ended in Sep. 2024 is calculated as

EBITDA per Share(Q: Sep. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-87.027/80.091
=-1.09

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crinetics Pharmaceuticals  (NAS:CRNX) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Crinetics Pharmaceuticals EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Crinetics Pharmaceuticals Business Description

Traded in Other Exchanges
Address
6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Executives
Richard Scott Struthers director, officer: See Remarks C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Jeff E. Knight officer: Chief Operating Officer CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti officer: Chief Development Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson officer: See Remarks 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Stephen F. Betz officer: Chief Scientific Officer 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Alan Seth Krasner officer: Chief Medical Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio director 225 SECOND AVENUE, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf director C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Ajay Madan officer: Chief Development Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301